ANRO vs AXSM

Analysts rate Alto Neuroscience, Inc.

(ANRO) a "Buy" — based on 8 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Axsome Therapeutics, Inc.

(AXSM) delivered a total return of +277. 9%, compared to +3. 7% for Alto Neuroscience, Inc. (ANRO). Over 10 years, the gap is even starker: AXSM returned +35. 5% versus ANRO's +3. 7%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Axsome Therapeutics, Inc.

(AXSM) is the lower-risk stock at 0. 63β versus Alto Neuroscience, Inc. 's 2. 60β — meaning ANRO is approximately 312% more volatile than AXSM relative to the S&P 500. On balance sheet safety, Alto Neuroscience, Inc. (ANRO) carries a lower debt/equity ratio of 3% versus 3% for Axsome Therapeutics, Inc. — giving it more financial flexibility in a downturn.

On earnings-per-share growth, the picture is similar: Axsome Therapeutics, Inc.

grew EPS 38. 6% year-over-year, compared to 12. 4% for Alto Neuroscience, Inc.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Alto Neuroscience, Inc.

(ANRO) is the more profitable company, earning 0. 0% net margin versus -28. 7% for Axsome Therapeutics, Inc. — meaning it keeps 0. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: ANRO leads at 0. 0% versus -26. 5% for AXSM. At the gross margin level — before operating expenses — AXSM leads at 92. 6%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Axsome Therapeutics, Inc.

(AXSM) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 63)). Alto Neuroscience, Inc. (ANRO) carries a higher beta of 2. 60 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (AXSM: +35. 5%, ANRO: +3. 7%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: ANRO is a small-cap quality compounder stock; AXSM is a mid-cap high-growth stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.